Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tsurumaki, Y.
Right arrow Articles by Hosaka, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsurumaki, Y.
Right arrow Articles by Hosaka, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 685-689
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997–1998 in Japan

Youko Tsurumaki*, Hinako Manda, Masaya Takei and Masaki Hosaka

Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd, 2399-1 Mitarai, Nogi, Shimotsuga, Tochigi 329-0114, Japan

The in vitro activity of gatifloxacin was determined for 873 isolates from various infections during 1997–1998 in Japan. Gatifloxacin was active against streptococci, Escherichia coli, Klebsiella pneumoniae, Moraxella catarrhalis, Haemophilus influenzae and Neisseria gonorrhoeae, with MIC90s of <=0.39 mg/L. The activity was two- to 32-fold greater than that of ciprofloxacin and levofloxacin against Gram-positive bacteria, and comparable to that against Gram-negative bacteria. Gatifloxacin was more active than the other quinolones against quinolone-resistant staphylococci, Enterococcus faecalis, E. coli and Enterobacter cloacae. It also had good activity against penicillin- or macrolide-resistant Streptococcus pneumoniae and ampicillin-resistant H. influenzae.

* Corresponding author. Tel: +81-280-562201; Fax: +81-280-571293; E-mail: fvbb0984{at}mb.infoweb.ne.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. Kishii, M. Takei, H. Fukuda, K. Hayashi, and M. Hosaka
Contribution of the 8-Methoxy Group to the Activity of Gatifloxacin against Type II Topoisomerases of Streptococcus pneumoniae
Antimicrob. Agents Chemother., January 1, 2003; 47(1): 77 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Takei, H. Fukuda, R. Kishii, Y. Kadowaki, Y. Atobe, and M. Hosaka
Contribution of the C-8-Methoxy Group of Gatifloxacin to Inhibition of Type II Topoisomerases of Staphylococcus aureus
Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3337 - 3338.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli, and M. R. Gismondo
Activity of levofloxacin and ciprofloxacin against urinary pathogens
J. Antimicrob. Chemother., July 1, 2001; 48(1): 37 - 45.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Fukuda, R. Kishii, M. Takei, and M. Hosaka
Contributions of the 8-Methoxy Group of Gatifloxacin to Resistance Selectivity, Target Preference, and Antibacterial Activity against Streptococcus pneumoniae
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1649 - 1653.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.